- Home
- SPRO vs SCOR Comparison
SPRO vs SCOR Comparison
Compare SPRO & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- SCOR
- Stock Information
- Founded
- SPRO 2013
- SCOR 1999
- Country
- SPRO United States
- SCOR United States
- Employees
- SPRO N/A
- SCOR N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- SCOR Business Services
- Sector
- SPRO Health Care
- SCOR Consumer Discretionary
- Exchange
- SPRO Nasdaq
- SCOR Nasdaq
- Market Cap
- SPRO 74.0M
- SCOR 64.4M
- IPO Year
- SPRO 2017
- SCOR 2007
- Fundamental
- Price
- SPRO $1.33
- SCOR $6.76
- Analyst Decision
- SPRO Strong Buy
- SCOR Buy
- Analyst Count
- SPRO 3
- SCOR 3
- Target Price
- SPRO $7.00
- SCOR $12.83
- AVG Volume (30 Days)
- SPRO 117.7K
- SCOR 15.8K
- Earning Date
- SPRO 08-05-2024
- SCOR 11-04-2024
- Dividend Yield
- SPRO N/A
- SCOR N/A
- EPS Growth
- SPRO N/A
- SCOR N/A
- EPS
- SPRO 0.33
- SCOR N/A
- Revenue
- SPRO $118,459,000.00
- SCOR $358,733,000.00
- Revenue This Year
- SPRO N/A
- SCOR N/A
- Revenue Next Year
- SPRO N/A
- SCOR $3.99
- P/E Ratio
- SPRO $4.06
- SCOR N/A
- Revenue Growth
- SPRO 118.43
- SCOR N/A
- 52 Week Low
- SPRO $0.99
- SCOR $6.31
- 52 Week High
- SPRO $1.89
- SCOR $20.97
- Technical
- Relative Strength Index (RSI)
- SPRO 49.07
- SCOR 34.75
- Support Level
- SPRO $1.28
- SCOR $6.31
- Resistance Level
- SPRO $1.37
- SCOR $7.24
- Average True Range (ATR)
- SPRO 0.06
- SCOR 0.44
- MACD
- SPRO 0.00
- SCOR 0.19
- Stochastic Oscillator
- SPRO 29.41
- SCOR 40.18
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. The platforms measure include televisions, mobile devices, computers, tablets, CTV devices and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada and Others. It provides solutions for Automotive, Digital Media, Financial Services, FMCG, Pharmaceutical , Retail, Technology and Travel.